Offering ‘Solutions for a Lifetime’ to cardiovascular patients

Cardiovascular diseases are the primary cause of death in developed countries. Hundreds of thousands of valves and vascular grafts made of synthetic material or animal tissue are implanted every year. These implants have a number of serious clinical limitations which vary according to the patient and condition treated.

New generation of cardiovascular implants

A new generation of implants promises to change this. Organ parts can be made from regrown, native-like tissue. There is no risk of inflammation or foreign-body response. The implants have the same self-renewing, regenerative capacity as the original organ and grow with the patient. Living implants will enable full recovery, improve quality of life and dramatically cut healthcare costs.

QTIS/e and Xeltis

As a culmination of our longstanding and successful research collaboration, QTIS/e and Xeltis recently decided to join our forces under the Xeltis name to further develop the COR platform of living implant devices. The joint company is at the forefront of these developments, working to bring ‘Solutions for a Lifetime’ to cardiovascular patients.

For more information on our COR platform, please visit us at www.xeltis.com.